Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Fibrinogen antagonists from Merck & Co.

Nov. 10, 1997

No Comments

Spotlight on thrombin inhibitors

Nov. 10, 1997

No Comments

ReoPro cleared in U.S. for expanded labeling

Nov. 7, 1997

No Comments

Saruplase efficacy demonstrated in large patient study

Nov. 7, 1997

No Comments

PEG-hirudin compared to established antithrombotic agents

Nov. 7, 1997

No Comments

Akzo Nobel prepares two series of thrombin inhibitors

Nov. 7, 1997

No Comments

Lefradafiban: oral prodrug for profound and sustained inhibition of platelet aggregation

Nov. 5, 1997

No Comments

Teijin licenses new thrombolytic from Schering AG

Nov. 5, 1997

No Comments

Factor Xa inhibitors prepared at DuPont Merck

Nov. 4, 1997

No Comments

New orally active thrombin inhibitors from Merck & Co.

Nov. 3, 1997

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Hematologic
RSS

Fibrinogen antagonists from Merck & Co.

Spotlight on thrombin inhibitors

ReoPro cleared in U.S. for expanded labeling

Saruplase efficacy demonstrated in large patient study

PEG-hirudin compared to established antithrombotic agents

Akzo Nobel prepares two series of thrombin inhibitors

Lefradafiban: oral prodrug for profound and sustained inhibition of platelet aggregation

Teijin licenses new thrombolytic from Schering AG

Factor Xa inhibitors prepared at DuPont Merck

New orally active thrombin inhibitors from Merck & Co.

Today's news in brief

Today's news in brief

Boryung invests $10M in Intuitive Machines for outer space R&D

Phase II Huntington’s tie-up with Novartis could edge $3B for PTC

Tolerogenic assets at heart of Cour-Genentech $940M autoimmune deal

Hematologic RSS

Hematologic
RSS